Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aus-131. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 7/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 1.00 |
| ▸ | TTR | P02766 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 7/20 | 0.74 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.74 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.74 |
| ▸ | RARA | P10276 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 1/20 | 0.45 |
| ▸ | RARG | P13631 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aus-131 SCHEMBL29467332 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL2002128 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43647 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43648 | 1.00 | ESR2 (1.00) | ESR2ESR1TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL17591903 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL31545730 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL19861143 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL17679253 | 0.91 | ESR2 (0.83) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL30720187 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 | |
| SCHEMBL4360255 | 0.90 | ESR2 (0.82) | ESR2ESR1TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612119-A | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | 西雅图儿童医院（DBA西雅图儿童研究所） | 2019-12-24 | — | — | CN | claimed |
| US-10463681-B2 | Combination therapy for skin disorders | M. ALPHABET 1, L.L.C. (US) | 2019-11-05 | — | — | US | claimed |
| EP-2575816-B1 | COMBINATION THERAPY FOR SKIN DISORDERS | NEXGEN DERMATOLOGICS INC (US) | 2019-01-02 | — | — | EP | claimed |
| US-20180153909-A1 | COMBINATION THERAPY FOR SKIN DISORDERS | NEXGEN DERMATOLOGICS, INC | 2018-06-07 | — | — | US | claimed |
| US-9884068-B2 | Combination therapy for skin disorders | M. ALPHABET 1, LLC (US) | 2018-02-06 | — | — | US | claimed |
| US-9333261-B2 | Combination therapy for skin disorders | M. ALPHABET 1, LLC (US) | 2016-05-10 | — | — | US | claimed |
| US-20140128351-A1 | COMBINATION THERAPY FOR SKIN DISORDERS | M. ALPHABET 1, LLC (US) | 2014-05-08 | — | — | US | claimed |
| CN-103608011-A | Methods and compositions suitable for preventing and treating hyperleptinemia | NESTEC SA | 2014-02-26 | — | — | CN | claimed |
| US-8653129-B2 | Combination therapy for skin disorders | M. ALPHABET 1, LLC (US) | 2014-02-18 | — | — | US | claimed |
| CN-101389328-B | Compositions and methods for inducing bone growth and inhibiting bone loss | NESTEC LTD | 2013-04-24 | — | — | CN | claimed |
| EP-1047420-A4 | MODULATION OF HAIR GROWTH | GILLETTE CO (US) | 2004-04-14 | — | — | EP | claimed |
| EP-1392239-A2 | USE OF ISOFLAVONOIDS IN COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE PROPHYLAXIS OR TREATMENT OF SENSITIVE SKIN | Beiersdorf AG (DE) | 2004-03-03 | — | — | EP | claimed |
| CN-1447689-A | Radiation protective agent | SHAPIRO ALLA (US) | 2003-10-08 | — | — | CN | claimed |
| WO-2002087517-A2 | USE OF ISOFLAVONOIDS IN COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE PROPHYLAXIS OR TREATMENT OF SENSITIVE SKIN | BEIERSDORF AG (DE) | 2002-11-07 | — | — | WO | claimed |
| EP-1153020-A4 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RES PTY LTD (AU) | 2002-08-21 | — | — | EP | claimed |
| EP-1153020-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | Novogen Research Pty. Ltd. (AU) | 2001-11-14 | — | — | EP | claimed |
| EP-1047420-A1 | MODULATION OF HAIR GROWTH | HANDELMAN, Joseph H. (US) | 2000-11-02 | — | — | EP | claimed |
| WO-2000049009-A1 | PRODUCTION OF ISOFLAVONE DERIVATIVES | NOVOGEN RESEARCH PTY. LTD. (AU) | 2000-08-24 | — | — | WO | claimed |
| US-5958946-A | APPLYING GLUCURONIC ACID | GILLETTE COMPANY, THE (A DELAWARE CORPORATION) | 1999-09-28 | — | — | US | claimed |
| WO-1999036067-A1 | MODULATION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463681-B2 | Combination therapy for skin disorders | NR5A1, CYP17A1, HSD17B2 | ESR2 183/4885ESR1 364/4885TTR 2315/4885 |
| US-20180153909-A1 | COMBINATION THERAPY FOR SKIN DISORDERS | NR5A1, CYP17A1, HSD17B2 | ESR2 183/4885ESR1 364/4885TTR 2315/4885 |
| US-20140128351-A1 | COMBINATION THERAPY FOR SKIN DISORDERS | NR5A1, CYP17A1, HSD17B2 | ESR2 183/4885ESR1 364/4885TTR 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.